These results will inform the design of future clinical research studies investigating the role of GLP-1 in treatment of obesity and cardiometabolic disease and provide support for potential measurement of GLP-1 as an indicator of treatment efficacy and/or compliance. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.